Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 2/2015

Open Access 01-02-2015 | Gynecologic Oncology

CD44 expression in curettage and postoperative specimens of endometrial cancer

Authors: Michał Wojciechowski, Tomasz Krawczyk, Janusz Śmigielski, Andrzej Malinowski

Published in: Archives of Gynecology and Obstetrics | Issue 2/2015

Login to get access

Abstract

Background

Adhesive molecules like CD44 are well defined key players in the metastatic cascade in many cancers, including endometrial cancer. They could play a role of markers of invasion, metastasis and prognostic factors.

Aim of the study

The aim of the study is to assess a possible role of the CD44 as a marker of invasion in endometrial cancer, both at the moment of preoperative workup and final staging.

Materials and methods

Available for analysis were archival specimens of 51 patients who had underwent curettage and surgery between 2002 and 2007. An immunohistochemical study for CD44 expression was performed in curettage and postoperative specimens. Normal endometrium of 20 randomly chosen patients was used as a control group.

Results

In endometrial cancer the expression of CD44 was significantly more intensive than in normal endometrium. In postoperative specimens, the CD44 expression was weaker in serous than in endometrioid cancer. There was no significant correlation between the adhesion molecule expression and clinicopathological features: grade,depth of invasion, cervical involvement, serosal and adnexal involvement, lymph-vascular space involvement, lymph node and distant metastases nor FIGO stage.

Conclusions

An increased expression of CD44 in endometrial cancer suggests its possible role in pathogenesis of this disease, however, it doesn’t seem to be crucial. Different expression of the CD44 in endometrioid and papillary-serous type may reflect different pathogenesis of these types of cancer. No statistically proved relation between the investigated molecule expression and clinicopathological parameters suggests scepticism about its use in diagnostic process of endometrial cancer.
Literature
1.
go back to reference American Cancer Society (2013) Cancer facts & figures 2013. American Cancer Society, Atlanta American Cancer Society (2013) Cancer facts & figures 2013. American Cancer Society, Atlanta
2.
go back to reference Bray F, Dos Santos Silva I, Moller H, Weiderpass E (2005) Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 14:1132–1142PubMedCrossRef Bray F, Dos Santos Silva I, Moller H, Weiderpass E (2005) Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 14:1132–1142PubMedCrossRef
3.
go back to reference Creasman WT, Odicino F, Maisonneuve P et al (2006) Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S105–S143PubMedCrossRef Creasman WT, Odicino F, Maisonneuve P et al (2006) Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S105–S143PubMedCrossRef
4.
go back to reference Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (2007) Cancer incidence in five continents. IARC Scientific Publications, Lyon Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (2007) Cancer incidence in five continents. IARC Scientific Publications, Lyon
5.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMedCrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMedCrossRef
6.
go back to reference ACOG Practice Bulletin (2005) Clinical management guidelines for obstetrician-gynecologists management of endometrial cancer. Manag Endomet Cancer 65:1–13 ACOG Practice Bulletin (2005) Clinical management guidelines for obstetrician-gynecologists management of endometrial cancer. Manag Endomet Cancer 65:1–13
8.
go back to reference Benedet JL, Bender H, Jones H III, Ngan HYS, Pecorelli S (2000) FIGO Committee on Gynecologic Oncology FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 70:209–262PubMedCrossRef Benedet JL, Bender H, Jones H III, Ngan HYS, Pecorelli S (2000) FIGO Committee on Gynecologic Oncology FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 70:209–262PubMedCrossRef
9.
go back to reference Benedetti Panici P, Basile S, Maneschi F et al (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716PubMedCrossRef Benedetti Panici P, Basile S, Maneschi F et al (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716PubMedCrossRef
10.
go back to reference ASTEC study group, Kitchener H, Swart AM, Qian Q et al (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 10:125–136CrossRef ASTEC study group, Kitchener H, Swart AM, Qian Q et al (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 10:125–136CrossRef
11.
go back to reference Bogani G, Dowdy SC, Cliby WA, Ghezzi F, Rossetti D, Mariani A (2014) Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence. J Obstet Gynaecol Res 40:301–311PubMedCrossRef Bogani G, Dowdy SC, Cliby WA, Ghezzi F, Rossetti D, Mariani A (2014) Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence. J Obstet Gynaecol Res 40:301–311PubMedCrossRef
12.
go back to reference Aplin AE, Howe A, Alahari SK, Juliano RL (1998) Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 50:197–263PubMed Aplin AE, Howe A, Alahari SK, Juliano RL (1998) Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 50:197–263PubMed
13.
go back to reference Mantur M, Wojszel J (2008) Cząsteczki adhezyjne oraz ich udział w procesie zapalnym i nowotworowym. Pol Merkur Lekarski 24:177–180PubMed Mantur M, Wojszel J (2008) Cząsteczki adhezyjne oraz ich udział w procesie zapalnym i nowotworowym. Pol Merkur Lekarski 24:177–180PubMed
14.
go back to reference Mareel M, Leroy A (2003) Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83:337–376PubMed Mareel M, Leroy A (2003) Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83:337–376PubMed
15.
16.
go back to reference Mizejewski GJ (1999) Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 222:124–138PubMedCrossRef Mizejewski GJ (1999) Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 222:124–138PubMedCrossRef
18.
go back to reference Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y (2002) CD44 in cancer. Crit Rev Clin Lab Sci 39:527–579PubMedCrossRef Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y (2002) CD44 in cancer. Crit Rev Clin Lab Sci 39:527–579PubMedCrossRef
19.
go back to reference Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18:260–267PubMedCrossRef Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18:260–267PubMedCrossRef
22.
go back to reference Golias CH, Chralabopoulos A, Peschos D, Maritsi D, Charalabopoulos P, Batistatou A (2005) Adhesion molecules in cancer invasion and metastasis. Hippokratia 9:106–114 Golias CH, Chralabopoulos A, Peschos D, Maritsi D, Charalabopoulos P, Batistatou A (2005) Adhesion molecules in cancer invasion and metastasis. Hippokratia 9:106–114
23.
go back to reference Günthert U, Hofmann M, Rudy W et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13–24PubMedCrossRef Günthert U, Hofmann M, Rudy W et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13–24PubMedCrossRef
24.
go back to reference Hofmann M, Rudy W, Günthert U et al (1993) A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res 53:1516–1521PubMed Hofmann M, Rudy W, Günthert U et al (1993) A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res 53:1516–1521PubMed
25.
go back to reference Afify AM, Craig S, Paulino AF, Stern R (2005) Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol 9:312–318PubMedCrossRef Afify AM, Craig S, Paulino AF, Stern R (2005) Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol 9:312–318PubMedCrossRef
26.
go back to reference Ayhan A, Tok EC, Bildirici I, Ayhan A (2001) Overexpression of CD44 variant 6 in human endometrial cancer and its prognostic significance. Gynecol Oncol 80:355–358PubMedCrossRef Ayhan A, Tok EC, Bildirici I, Ayhan A (2001) Overexpression of CD44 variant 6 in human endometrial cancer and its prognostic significance. Gynecol Oncol 80:355–358PubMedCrossRef
27.
go back to reference Fujita N, Yaegashi N, Ide Y et al (1994) Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 54:3922–3928PubMed Fujita N, Yaegashi N, Ide Y et al (1994) Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 54:3922–3928PubMed
28.
go back to reference Leblanc M, Poncelet C, Soriano D et al (2001) Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchows Arch 438:78–85PubMedCrossRef Leblanc M, Poncelet C, Soriano D et al (2001) Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchows Arch 438:78–85PubMedCrossRef
29.
30.
go back to reference Tokumo K, Kodama J, Seki N, Miyagi Y, Yoshinouchi M, Kudo T (1998) CD44 exon v6 is not implicated in the progression and metastasis of endometrial cancer. Cancer Lett 125:221–225PubMedCrossRef Tokumo K, Kodama J, Seki N, Miyagi Y, Yoshinouchi M, Kudo T (1998) CD44 exon v6 is not implicated in the progression and metastasis of endometrial cancer. Cancer Lett 125:221–225PubMedCrossRef
31.
go back to reference Yorishima T, Nagai N, Ohama K (1997) Expression of CD44 alternative splicing variants in primary and lymph node metastatic lesions of gynecological cancer. Hiroshima J Med Sci 46:21–29PubMed Yorishima T, Nagai N, Ohama K (1997) Expression of CD44 alternative splicing variants in primary and lymph node metastatic lesions of gynecological cancer. Hiroshima J Med Sci 46:21–29PubMed
32.
go back to reference Stokes GN, Shelton JB Jr, Zahn CM, Kendall BS (2002) Association of CD44 isoform immunohistochemical expression with myometrial and vascular invasion in endometrioid endometrial carcinoma. Gynecol Oncol 84:58–61PubMedCrossRef Stokes GN, Shelton JB Jr, Zahn CM, Kendall BS (2002) Association of CD44 isoform immunohistochemical expression with myometrial and vascular invasion in endometrioid endometrial carcinoma. Gynecol Oncol 84:58–61PubMedCrossRef
33.
go back to reference Zagorianakou N, Ioachim E, Mitselou A et al (2003) Glycoprotein CD44 expression in normal, hyperplasic and neoplastic endometrium. An immunohistochemical study including correlations with p53, steroid receptor status and proliferative indices (PCNA, MIB1). Eur J Gynaecol Oncol 24:500–504PubMed Zagorianakou N, Ioachim E, Mitselou A et al (2003) Glycoprotein CD44 expression in normal, hyperplasic and neoplastic endometrium. An immunohistochemical study including correlations with p53, steroid receptor status and proliferative indices (PCNA, MIB1). Eur J Gynaecol Oncol 24:500–504PubMed
34.
go back to reference Hosford S, Elliott J, Ma ZW et al (2003) CD44 expression in papillary serous endometrial carcinoma. Int J Gynecol Cancer 13:480–484PubMedCrossRef Hosford S, Elliott J, Ma ZW et al (2003) CD44 expression in papillary serous endometrial carcinoma. Int J Gynecol Cancer 13:480–484PubMedCrossRef
35.
go back to reference Hoshimoto K, Yamauchi N, Takazawa Y, Onda T, Taketani Y, Fukayama M (2003) CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker. Pathol Res Pract 199:71–77PubMedCrossRef Hoshimoto K, Yamauchi N, Takazawa Y, Onda T, Taketani Y, Fukayama M (2003) CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker. Pathol Res Pract 199:71–77PubMedCrossRef
36.
37.
go back to reference Saegusa M, Hashimura M, Okayasu I (1998) CD44 expression in normal, hyperplastica and malignant endometrium. J Pathol 184:297–306PubMedCrossRef Saegusa M, Hashimura M, Okayasu I (1998) CD44 expression in normal, hyperplastica and malignant endometrium. J Pathol 184:297–306PubMedCrossRef
38.
go back to reference Indinnimeo M, Cicchini C, Giarnieri E, Stazi A, Mingazzini PL, Stipa V (2003) Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma. Oncol Rep 10:1875–1877PubMed Indinnimeo M, Cicchini C, Giarnieri E, Stazi A, Mingazzini PL, Stipa V (2003) Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma. Oncol Rep 10:1875–1877PubMed
39.
go back to reference Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Günthert U (1994) Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 124:71–82PubMedCrossRef Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Günthert U (1994) Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 124:71–82PubMedCrossRef
40.
go back to reference Inoue M (2001) Current molecular aspects of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer 11:339–348PubMedCrossRef Inoue M (2001) Current molecular aspects of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer 11:339–348PubMedCrossRef
41.
go back to reference Yabushita H, Kishida T, Fusano K et al (2005) Role of hyaluronan and hyaluronan synthase in endometrial cancer. Oncol Rep 13:1101–1105PubMed Yabushita H, Kishida T, Fusano K et al (2005) Role of hyaluronan and hyaluronan synthase in endometrial cancer. Oncol Rep 13:1101–1105PubMed
42.
go back to reference Yaegashi N, Fujita N, Yajima A, Nakamura M (1995) Menstrual cycle dependent expression of CD44 in normal human endometrium. Hum Pathol 26:862–865PubMedCrossRef Yaegashi N, Fujita N, Yajima A, Nakamura M (1995) Menstrual cycle dependent expression of CD44 in normal human endometrium. Hum Pathol 26:862–865PubMedCrossRef
43.
go back to reference Poncelet C, Leblanc M, Walker-Combrouze F et al (2002) Expression of cadherins and CD44 isoforms in human endometrium and peritoneal endometriosis. Acta Obstet Gynecol Scand 81:195–203PubMedCrossRef Poncelet C, Leblanc M, Walker-Combrouze F et al (2002) Expression of cadherins and CD44 isoforms in human endometrium and peritoneal endometriosis. Acta Obstet Gynecol Scand 81:195–203PubMedCrossRef
44.
go back to reference Soslow RA, Shen PU, Isacson C, Chung MH (1998) The CD44v6-negative phenotype in high-grade uterine carcinomas correlates with serous histologic subtype. Mod Pathol 11:194–199PubMed Soslow RA, Shen PU, Isacson C, Chung MH (1998) The CD44v6-negative phenotype in high-grade uterine carcinomas correlates with serous histologic subtype. Mod Pathol 11:194–199PubMed
Metadata
Title
CD44 expression in curettage and postoperative specimens of endometrial cancer
Authors
Michał Wojciechowski
Tomasz Krawczyk
Janusz Śmigielski
Andrzej Malinowski
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 2/2015
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-014-3407-1

Other articles of this Issue 2/2015

Archives of Gynecology and Obstetrics 2/2015 Go to the issue